Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Genetic Epidemiology of Rotator Cuff Tears: the CuffGEN Study
NCT04831164
Recruiting
Rotator cuff tear is one of the most common reasons to seek musculoskeletal care, and cuff repair is one of the fastest growing ambulatory surgery procedures. However, the etiology of cuff tears, reasons for variability treatment success, and causes of FI are poorly understood. A large-scale genome-wide association studies (GWAS) using imaging-verified rotator cuff tear cases and controls can address limitations in rigor of prior research and assess the genetic basis of FI and functional outcome... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
11/17/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Rotator Cuff Tears
Register for Updates
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
NCT06681623
Recruiting
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
11/15/2024
Locations: Neurology Center of New England P.C., Foxboro, Massachusetts
Conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Register for Updates
Patient-centered, Optimal Integration of Survivorship and Palliative Care
NCT04900935
Recruiting
The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE feasible to deliver and acceptable to patients * what is the effect of POISE on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive eit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Register for Updates
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699
Recruiting
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumor
Register for Updates
The Myelin Disorders Biorepository Project
NCT03047369
Recruiting
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2024
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Register for Updates
Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis
NCT06569147
Recruiting
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: AL Amyloidosis
Register for Updates
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
NCT06517186
Recruiting
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
11/14/2024
Locations: Mass General Brigham, Boston, Massachusetts
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
CHW Intervention to Improve Nutrition Security of Patients with Hypertension
NCT06358417
Recruiting
The goal of this study is to implement and evaluate a randomized pilot study of a 4-month Nutrition-enhanced community health worker (CHW) intervention for primary care patients with nutrition insecurity and poorly controlled hypertension. The nutrition intervention will be added to the pre-existing Massachusetts General Hospital CHW hypertension (Basic CHW) program that provides hypertension education, coaching about adherence to medications and primary care visits, and home BP cuffs and promot... Read More
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
11/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypertension, Nutrition, Healthy, Food Insecurity, Community Health Worker
Register for Updates
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
NCT06302621
Recruiting
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Register for Updates
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
NCT06265532
Recruiting
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
11/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
11/14/2024
Locations: Boston Children's Hospital Comprehensive Epilepsy Center, Boston, Massachusetts
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Register for Updates
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882
Recruiting
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2024
Locations: Vanda Investigational Site, Boston, Massachusetts
Conditions: Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
Register for Updates